![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Barr Confirms Kos is Seeking Court Order to Block Generic Niaspan
Barr Confirms Kos is Seeking Court Order to Block Generic Niaspan
March 10, 2005
Barr Pharmaceuticals has confirmed that Kos Pharmaceuticals has filed a motion for a temporary restraining order and a preliminary injunction in the United States District Court for the Southern District of New York seeking to prevent Barr from launching generic versions of Kos' Niaspan 500-mg, 750-mg and 1,000-mg extended-release tablets (Niacin extended-release tablets) following final U.S. Food & Drug Administration (FDA) approval.
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19339520&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct